raloxifene hydrochloride has been researched along with Atypical Ductal Hyperplasia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Laws, A; Punglia, RS | 1 |
| Kane, RL; Shamilyan, T; Tuttle, TM; Virnig, BA; Wang, SY | 1 |
| Clarfeld, RB; Costantino, JP; Grant, MD; McCaskill-Stevens, W; Vogel, VG; Wickerham, DL; Wolmark, N | 1 |
| Eng-Wong, J; Faupel-Badger, JM; Prindiville, SA; Venzon, D; Vonderhaar, BK; Zujewski, JA | 1 |
| Aumiller, J | 1 |
| Osborne, MP; Rosenbaum Smith, SM | 1 |
4 review(s) available for raloxifene hydrochloride and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast Cancer.
Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Raloxifene Hydrochloride; Secondary Prevention; Tamoxifen | 2023 |
Ductal carcinoma in situ: risk factors and impact of screening.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Chemoprevention; Female; Hormone Replacement Therapy; Humans; Incidence; Mammography; Mass Screening; Middle Aged; Multicenter Studies as Topic; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Tamoxifen; Young Adult | 2010 |
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Chemoprevention; Clinical Trials as Topic; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperplasia; Incidence; Multicenter Studies as Topic; Pulmonary Embolism; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome | 2010 |
Breast cancer chemoprevention.
Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Female; Humans; Middle Aged; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen | 2000 |
1 trial(s) available for raloxifene hydrochloride and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.
Topics: Adult; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Estradiol; Female; Humans; Middle Aged; Neoplasm Invasiveness; Pilot Projects; Premenopause; Prolactin; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Sex Hormone-Binding Globulin | 2006 |
1 other study(ies) available for raloxifene hydrochloride and Atypical Ductal Hyperplasia
| Article | Year |
|---|---|
[Drug prevention and proper nutrition. Prevention of breast cancer as in coronary heart disease?].
Topics: Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Neoplasm Recurrence, Local; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen | 2007 |